IP Library Granted Patent US 8,153,594
Granted Patent B2
US 8,153,594 · App. 12/621,303 · Granted Apr 10, 2012

Tacrolimus standard and methods of using same

Assignee: Siemens Healthcare Diagnostics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,153,594
App. No.
12/621,303
Granted
Apr 10, 2012
Kind
B2
Abstract

A composition and kit useful as a tacrolimus standard solution for immunoassays, and methods for making and using same. The composition and kits include a known amount of tacrolimus or a derivative thereof, and a non-specific protein capable of forming a complex with the tacrolimus or derivative thereof. The standard solution may be used to generate calibration curves for an immunoassay or to check the precision of an analytical instrument.

Claims (10)

1. A composition suitable for use as a standard in an assay, comprising:

a solution having a known amount of tacrolimus or a derivative thereof and a protein non-specific for tacrolimus and capable of forming a soluble complex with the tacrolimus or the derivative thereof, the protein being at least 95% fatty acid free and the ratio of non-specific protein to tacrolimus being in the range of 25,000:1 to 1000:1 on a weight basis, the solution further comprising a polyoxylated caster oil in an amount of 0.01% to 0.5% by weight.

2. The composition of claim 1 , wherein the solution comprises an aqueous solution and the complex is water soluble.

3. The composition of claim 1 , wherein the solution is free of alkanol solvents.

4. The composition of claim 1 , wherein the solution is free of methanol.

5. The composition of claim 1 , wherein the solution is free of proteins capable of specifically binding tacrolimus.

6. The composition of claim 1 , wherein the protein comprises albumin.

7. The composition of claim 1 , wherein the albumin comprises fatty acid free bovine serum albumin.

8. The composition of claim 1 , further comprising a hemolysate.

9. The composition of claim 1 , further comprising a label capable of forming a complex with an antibody and suitable for producing a detectable signal.

Assignments (1)
MERGER Recorded Nov 30, 2009
From: DADE BEHRING INC.
To: SIEMENS HEALTHCARE DIAGNOSTICS INC.
Reel/Frame 023580/0337 →
Continuity (2)
Division 11455956 · Jun 20, 2006
Related Publication 20100062459A1 · Mar 11, 2010